Literature DB >> 11870587

A new subtype of a congenital disorder of glycosylation (CDG) with mild clinical manifestations.

B Assmann1, R Hackler, V Peters, J R Schaefer, T Arndt, E Mayatepek, J Jaeken, G F Hoffmann.   

Abstract

A boy with an unspecific symptomatology consisting of mental retardation, strabismus, hypotonia and mild ataxia was diagnosed with a congenital disorder of glycosylation (CDG). Neither cerebellar atrophy nor dysmorphic features were present. The serum transferrin band pattern obtained by isoelectric focusing(IEF) showed a strongly elevated disialotransferrin band together with only slightly elevated asialotransferrin, thus a type I pattern. This is a new CDG classified CDG-x since CDG-la, -b, -c, -d and -e were excluded. Quantitative differences to the type 1 pattern of a CDG-la patient with a moderate to severe course were confirmed by densitometric evaluation of the gels and by SDS gel electrophoresis. Liver biopsy showed lysosomal inclusions suggesting a pre-Golgi defect. This patient's case supports the approach to include isoelectric focusing of serum transferrin in the diagnostic work-up of patients with unexplained symptoms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11870587     DOI: 10.1055/s-2001-20407

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

1.  Life with too much polyprenol: polyprenol reductase deficiency.

Authors:  J E H Gründahl; Z Guan; S Rust; J Reunert; B Müller; I Du Chesne; K Zerres; S Rudnik-Schöneborn; N Ortiz-Brüchle; M G Häusler; J Siedlecka; E Swiezewska; C R H Raetz; T Marquardt
Journal:  Mol Genet Metab       Date:  2011-12-29       Impact factor: 4.797

2.  SRD5A3-CDG: Expanding the phenotype of a congenital disorder of glycosylation with emphasis on adult onset features.

Authors:  Patricia G Wheeler; Bobby G Ng; Laura Sanford; V Reid Sutton; Dennis W Bartholomew; Matthew T Pastore; Michael J Bamshad; Martin Kircher; Kati J Buckingham; Deborah A Nickerson; Jay Shendure; Hudson H Freeze
Journal:  Am J Med Genet A       Date:  2016-08-02       Impact factor: 2.802

3.  A novel cerebello-ocular syndrome with abnormal glycosylation due to abnormalities in dolichol metabolism.

Authors:  Eva Morava; Ron A Wevers; Vincent Cantagrel; Lies H Hoefsloot; Lihadh Al-Gazali; Jeroen Schoots; Arno van Rooij; Karin Huijben; Connie M A van Ravenswaaij-Arts; Marjolein C J Jongmans; Jolanta Sykut-Cegielska; Georg F Hoffmann; Peter Bluemel; Maciej Adamowicz; Jeroen van Reeuwijk; Bobby G Ng; Jorieke E H Bergman; Hans van Bokhoven; Christian Körner; Dusica Babovic-Vuksanovic; Michel A Willemsen; Joseph G Gleeson; Ludwig Lehle; Arjan P M de Brouwer; Dirk J Lefeber
Journal:  Brain       Date:  2010-09-17       Impact factor: 13.501

4.  Komrower Lecture. Congenital disorders of glycosylation (CDG): it's all in it!

Authors:  J Jaeken
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

5.  Phenotypic Expansion of Congenital Disorder of Glycosylation Due to SRD5A3 Null Mutation.

Authors:  Beyhan Tuysuz; Davut Pehlivan; Ahmet Özkök; Shalini Jhangiani; Cengiz Yalcinkaya; Çiğdem Aktuğlu Zeybek; Donna Marie Muzny; James R Lupski; Richard Gibbs; Jaak Jaeken
Journal:  JIMD Rep       Date:  2015-07-29

6.  Congenital disorder of glycosylation type Ix: review of clinical spectrum and diagnostic steps.

Authors:  E Morava; H Wosik; J Kárteszi; M Guillard; M Adamowicz; J Sykut-Cegielska; K Hadzsiev; R A Wevers; D J Lefeber
Journal:  J Inherit Metab Dis       Date:  2008-05-20       Impact factor: 4.750

7.  Adult phenotype and further phenotypic variability in SRD5A3-CDG.

Authors:  Bülent Kara; Özgecan Ayhan; Gülden Gökçay; Nurdan Başboğaoğlu; Aslıhan Tolun
Journal:  BMC Med Genet       Date:  2014-01-16       Impact factor: 2.103

8.  Identification of a case of SRD5A3-congenital disorder of glycosylation (CDG1Q) by exome sequencing.

Authors:  Neerja Gupta; Gaurav Verma; Madhulika Kabra; Sunita Bijarnia-Mahay; Aparna Ganapathy
Journal:  Indian J Med Res       Date:  2018-04       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.